1. Home
  2. BBIO
  3. BBIO News

Latest BridgeBio Pharma Inc. (BBIO) News on December 22, 2024

BBIO

MT Newswires

9 days ago

BridgeBio's Acoramidis Recommended by EU Panel for Transthyretin Amyloid Cardiomyopathy

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BBIO

GlobeNewswire

9 days ago

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
BBIO

Zacks

23 days ago

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BBIO

Zacks

a month ago

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
BBIO

Zacks

a month ago

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

BBIO

Morningstar Research

a month ago

Analyst Report: BridgeBio Pharma, Inc.

BridgeBio price target raised to $45 from $42 at BofA
BBIO

TipRanks

a month ago

BridgeBio price target raised to $45 from $42 at BofA

BBIO

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

BBIO

MT Newswires

a month ago

Sector Update: Health Care

BBIO

MT Newswires

a month ago

Update: BridgeBio Pharma Shares Surge After Obtaining FDA Approval for Attruby

BBIO

MT Newswires

a month ago

UBS Adjusts BridgeBio Pharma Price Target to $54 From $47, Maintains Buy Rating

BridgeBio Soars After Drug Gets Nod in Rare Heart Condition
BBIO

Bloomberg

a month ago

BridgeBio Soars After Drug Gets Nod in Rare Heart Condition

BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
BBIO

Investor's Business Daily

a month ago

BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
BBIO

Benzinga

a month ago

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

BBIO

MT Newswires

a month ago

BridgeBio Pharma Obtains FDA Approval of Attruby

FDA approves BridgeBio’s Attruby for ATTR-CM treatment
BBIO

Pharmaceutical Technology

a month ago

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BBIO

GlobeNewswire

a month ago

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BridgeBio heart drug approved by FDA, setting up battle with Pfizer
BBIO

BioPharma Dive

a month ago

BridgeBio heart drug approved by FDA, setting up battle with Pfizer

Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
BBIO

Insider Monkey

a month ago

Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
BBIO

Benzinga

a month ago

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
BBIO

Simply Wall St.

a month ago

The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
BBIO

GlobeNewswire

a month ago

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
BBIO

GlobeNewswire

a month ago

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
BBIO

Simply Wall St.

a month ago

BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BBIO

Morningstar Research

a month ago

Analyst Report: BridgeBio Pharma, Inc.

BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates
BBIO

Zacks

a month ago

BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates

BBIO

MT Newswires

a month ago

BridgeBio Pharma's Q3 Loss Narrows, Revenue Declines

BBIO

Associated Press Finance

a month ago

BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
BBIO

GlobeNewswire

a month ago

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
BBIO

GlobeNewswire

2 months ago

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
BBIO

Zacks

2 months ago

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
BBIO

GlobeNewswire

2 months ago

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years
BBIO

Simply Wall St.

2 months ago

Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years

BBIO

MT Newswires

2 months ago

Scotiabank Initiates BridgeBio Pharma at Sector Outperform With $44 Price Target

3 Top Stocks That Could Still Rocket Higher in 2024
BBIO

Motley Fool

3 months ago

3 Top Stocks That Could Still Rocket Higher in 2024

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
BBIO

GlobeNewswire

3 months ago

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

BBIO

MT Newswires

3 months ago

Oppenheimer Initiates BridgeBio Pharma at Perform

5 FDA decisions to watch in the fourth quarter
BBIO

BioPharma Dive

3 months ago

5 FDA decisions to watch in the fourth quarter

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
BBIO

Benzinga

3 months ago

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

BBIO

Morningstar Research

3 months ago

Analyst Report: BridgeBio Pharma, Inc.

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Completes Phase 3 BBP-418 Trial Enrollment

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
BBIO

GlobeNewswire

3 months ago

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
BBIO

GlobeNewswire

3 months ago

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

BBIO

MT Newswires

3 months ago

Sector Update: Health Care Stocks Steady Premarket Tuesday

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Says Infigratinib Receives US FDA Breakthrough Therapy Designation

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
BBIO

GlobeNewswire

3 months ago

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly
BBIO

The Wall Street Journal

3 months ago

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly

BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
BBIO

Benzinga

3 months ago

BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition

BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine
BBIO

BioPharma Dive

3 months ago

BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Cancels Development of Congenital Adrenal Hyperplasia Treatment

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Gets RMAT Designation for Gene Therapy Targeting Canavan Disease

BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
BBIO

GlobeNewswire

3 months ago

BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
BBIO

GlobeNewswire

3 months ago

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

4 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO

MT Newswires

4 months ago

Piper Sandler Initiates BridgeBio Pharma at Overweight

BBIO

MT Newswires

4 months ago

Sector Update: Health Care Stocks Softer in Afternoon Trading

Why Is BridgeBio Pharma Stock Trading Higher On Friday?
BBIO

Benzinga

4 months ago

Why Is BridgeBio Pharma Stock Trading Higher On Friday?

BBIO

MT Newswires

4 months ago

BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
BBIO

GlobeNewswire

4 months ago

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug
BBIO

The Wall Street Journal

4 months ago

Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
BBIO

GlobeNewswire

4 months ago

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

BridgeBio Pharma to Participate in September Investor Events
BBIO

GlobeNewswire

4 months ago

BridgeBio Pharma to Participate in September Investor Events

BBIO

MT Newswires

4 months ago

BridgeBio Partners With CarDS Lab for Transthyretin Amyloid Cardiomyopathy Study

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
BBIO

GlobeNewswire

4 months ago

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

BBIO

MT Newswires

4 months ago

BridgeBio Pharma Launches GondolaBio Joint Venture

BridgeBio sends rare disease drugs to new company
BBIO

BioPharma Dive

4 months ago

BridgeBio sends rare disease drugs to new company

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
BBIO

GlobeNewswire

4 months ago

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

4 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
BBIO

Simply Wall St.

5 months ago

BridgeBio Pharma Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
BBIO

Zacks

5 months ago

BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates

BBIO

Associated Press Finance

5 months ago

BridgeBio Pharma: Q2 Earnings Snapshot

BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update

BBIO

MT Newswires

5 months ago

BridgeBio Pharma Names New COO

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
BBIO

GlobeNewswire

5 months ago

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
BBIO

Insider Monkey

6 months ago

BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?

BBIO

MT Newswires

6 months ago

BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug
BBIO

Investor's Business Daily

7 months ago

BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug

BBIO

MT Newswires

7 months ago

BridgeBio Pharma Phase 2 Trial of Infigratinib Shows 'Continued Well-Tolerated Safety Profile'; Starts Phase 3 Trial Enrollment

BridgeBio data show sustained benefit for achondroplasia drug
BBIO

BioPharma Dive

7 months ago

BridgeBio data show sustained benefit for achondroplasia drug

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
BBIO

GlobeNewswire

7 months ago

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
BBIO

GlobeNewswire

7 months ago

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BBIO

GlobeNewswire

7 months ago

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO

MT Newswires

7 months ago

UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

Party Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings Forecasts
BBIO

Simply Wall St.

7 months ago

Party Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings Forecasts

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population

What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
BBIO

Simply Wall St.

8 months ago

What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today

BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
BBIO

Simply Wall St.

8 months ago

BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations

BridgeBio Oncology Therapeutics launches with $200m funding
BBIO

Pharmaceutical Technology

8 months ago

BridgeBio Oncology Therapeutics launches with $200m funding

BBIO

MT Newswires

8 months ago

BridgeBio Pharma Shares Decline After Q1 Financial Results

BBIO

Associated Press Finance

8 months ago

BridgeBio Pharma: Q1 Earnings Snapshot

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
BBIO

GlobeNewswire

8 months ago

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
BBIO

GlobeNewswire

8 months ago

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

BridgeBio spinout launches with $200M for KRAS cancer drugs
BBIO

BioPharma Dive

8 months ago

BridgeBio spinout launches with $200M for KRAS cancer drugs

Share on Social Networks: